Vaxcyte, Inc.
PCVX
$54.58
-$1.63-2.90%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 39.25% | 53.53% | 56.05% | 56.62% | 53.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.18% | 34.35% | 22.86% | 24.36% | 21.69% |
| Operating Income | -62.18% | -34.35% | -22.86% | -24.36% | -21.69% |
| Income Before Tax | -65.25% | -29.46% | -10.12% | -16.67% | -15.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -65.25% | -29.46% | -10.12% | -16.67% | -15.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -65.25% | -29.46% | -10.12% | -16.67% | -15.33% |
| EBIT | -62.18% | -34.35% | -22.86% | -24.36% | -21.69% |
| EBITDA | -61.28% | -33.52% | -21.90% | -23.44% | -21.01% |
| EPS Basic | -48.34% | -6.44% | 11.12% | 5.69% | 6.81% |
| Normalized Basic EPS | -48.35% | -6.44% | 11.11% | 5.68% | 6.80% |
| EPS Diluted | -48.34% | -6.44% | 11.12% | 5.69% | 6.81% |
| Normalized Diluted EPS | -48.35% | -6.44% | 11.11% | 5.68% | 6.80% |
| Average Basic Shares Outstanding | 11.58% | 19.32% | 22.50% | 23.65% | 25.58% |
| Average Diluted Shares Outstanding | 11.58% | 19.32% | 22.50% | 23.65% | 25.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |